Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers

详细信息    查看全文

• 作者：Jessica A. Waller^a ; ^{wallerjessica14@gmail.com} ; Joseph A. Tamm^b ; Aicha Abdourahman^b ; Alan L. Pehrson^a ; Yan Li^a ; Manuel Cajina^c ; Connie Sá ; nchez^a ; ^{connie_sanchez@clin.au.dk}
• 关键词：Multimodal ; Neuroplasticity ; Neurodevelopment ; Immediate early gene ; Transcription regulation
• 刊名：European Neuropsychopharmacology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：27
• 期：2
• 页码：192-203
• 全文大小：887 K
• 卷排序：27

文摘

The multimodal antidepressant vortioxetine displays an antidepressant profile distinct from those of conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and possesses cognitive-enhancing properties in preclinical and clinical studies. Recent studies have begun to investigate molecular mechanisms that may differentiate vortioxetine from other antidepressants. Acute studies in adult rats and chronic studies in a middle-aged mouse model reveal upregulation of several markers that play a central role in synaptic plasticity. However, the effect of chronic vortioxetine treatment on expression of neuroplasticity and neurodevelopmental biomarkers in naïve rats has not been evaluated. In the present study, we demonstrate that vortioxetine at a range of doses regulates expression of genes associated with plasticity in the frontal cortex, hippocampus, region encompassing the amygdala, as well as in blood, and displays similar effects relative to the SSRI fluoxetine in adult naïve rats. These genes encode immediate early genes (IEGs), translational regulators, and the neurodevelopmental marker Sema4g. Similar findings detected in brain regions and in blood provide a potential translational impact, and vortioxetine appears to consistently regulate signaling in these networks of neuroplasticity and developmental markers.